Takeda Pharmaceutical (TAK) Cash from Operations Growth (1y) (2019 - 2026)
Powered by 
Analysis
Takeda Pharmaceutical (TAK) Cash from Operations Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 122.18% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -33.32% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 63.07% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -11.73% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 243.47% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 107.90% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 1,034.67% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 63.59% |
| 10 | Takeda Pharmaceutical | 2.61 Bn | -3.19 Bn | 5.10 Bn | -46.22% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -46.22% |
| Mar 31, 2026 | -67.36% |
| Dec 31, 2025 | -3.92% |
| Sep 30, 2025 | 248.38% |
| Jun 30, 2025 | 36.09% |
| Mar 31, 2025 | -22.54% |
| Dec 31, 2024 | 154.78% |
| Sep 30, 2024 | -60.20% |
| Jun 30, 2024 | 62.26% |
| Mar 31, 2024 | 169.11% |
| Dec 31, 2023 | -62.99% |
| Sep 30, 2023 | -12.55% |
| Jun 30, 2023 | 3.51% |
| Mar 31, 2023 | -51.36% |
| Dec 31, 2022 | -12.43% |
| Sep 30, 2022 | 155.54% |
| Jun 30, 2022 | -57.27% |
| Mar 31, 2022 | -62.09% |
| Dec 31, 2021 | 46.56% |
| Sep 30, 2021 | -8.64% |